FDA Approves First Ebola Virus Treatment
Good news! This week, for the first time ever, the FDA has approved a treatment for the Ebola Virus. Inmazeb, which is a mixture of three monoclonal antibodies, has been OK’d by the US Food and Drug Administration for use in both adults and children.
Inmazeb works by blocking the virus’ ability to enter the human cell. It does so by binding to the virus’ glycoprotein and interfere with its ability to fuse to the cell membrane. In the study of 382 adult and pediatric patients, 154 patients received Inmazeb and 168 received a control treatment. Inmazeb performed better than the control after 28 days, seeing a mortality rate of only 33.8% compared to the control’s rate of 51%.